Literature DB >> 31160469

Protamine Sulfate Induces Mitochondrial Hyperpolarization and a Subsequent Increase in Reactive Oxygen Species Production.

Rabia Ramzan1, Susanne Michels2, Petra Weber2, Annika Rhiel2, Marc Irqsusi2, Ardawan J Rastan2, Carsten Culmsee2, Sebastian Vogt2.   

Abstract

Protamine sulfate (PS) is widely used in heart surgery as an antidote for heparin, albeit its pharmacological effects are not fully understood and applications are often accompanied by unwanted side effects. Here we show the effect of PS on mitochondrial bioenergetics profile resulting in mitochondrial reactive oxygen species (ROS) production. Polarographic measurements were performed in parallel to membrane potential and ROS measurements by FACS analyzer using tetramethylrhodamine ethyl ester and MitoSOX fluorescent dyes, respectively. PS inhibited intact rat heart mitochondrial respiration (stimulated by ADP) to 76% (P < 0.001) from the baseline of 51.6 ± 6.9 to 12.4 ± 2.3 nmol O2⋅min-1⋅ml-1 The same effect was found when respiration was inhibited by antimycin A (101.0 ± 8.9 vs. 38.0 ± 9.9 nmol O2 ⋅min-1⋅ml-1, P < 0.001) and later stimulated by substrates of cytochrome oxidase (CytOx) i.e., ascorbate and tetramethyl phenylene diamine, suggesting that PS exerted its effect through inhibition of CytOx activity. Furthermore, the inhibition of mitochondrial respiration by PS was concentration dependent and accompanied by hyperpolarization of the mitochondrial membrane potential (Δψ m), i.e., 18% increase at 50 µg/ml and an additional 3.3% increase at 250 µg/ml PS compared with control. This effect was associated with a strong consequent increase in the production of ROS, i.e., 85% and 88.6% compared with control respectively. We propose that this excessive increase in ROS concentrations results in mitochondrial dysfunction and thus might relate to the "protamine reaction," contributing to the development of various cardiovascular adverse effects.
Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31160469     DOI: 10.1124/jpet.119.257725

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Ulinastatin attenuates protamine-induced cardiotoxicity in rats by inhibiting tumor necrosis factor alpha.

Authors:  Hisashi Fukushima; Takeshi Oguchi; Hiroaki Sato; Yosuke Nakadate; Tamaki Sato; Keisuke Omiya; Akiko Kawakami; Toru Matsuoka; Takashi Matsukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-08       Impact factor: 3.000

Review 2.  Stress-mediated generation of deleterious ROS in healthy individuals - role of cytochrome c oxidase.

Authors:  Rabia Ramzan; Sebastian Vogt; Bernhard Kadenbach
Journal:  J Mol Med (Berl)       Date:  2020-04-20       Impact factor: 4.599

3.  Effect of Lidocaine Pre-Treatment on Protamine-Induced Pulmonary Vascular Reaction During the Repair of Congenital Heart Disease.

Authors:  Hong-Wu Wang; Yi-Jin Hu; Guo-Lin Wang
Journal:  Int J Gen Med       Date:  2021-06-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.